Last reviewed · How we verify
Saliva
At a glance
| Generic name | Saliva |
|---|---|
| Sponsor | Versailles Hospital |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- GCF and Saliva Levels of IL-36α in Periodontal Disease (NA)
- Kissing as a Protective Factor Against Acidic pH in Saliva (NA)
- Blood Donor CVD 5000 (PHASE4)
- A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients (NA)
- Analytical Evaluation of the Endotest® Diagnostic (NA)
- Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV) (NA)
- Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
- Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saliva CI brief — competitive landscape report
- Saliva updates RSS · CI watch RSS
- Versailles Hospital portfolio CI